Evaluation of Safety and Efficacy of Autologous Platelet-Rich Fibrin in the Treatment of Psoriasis Vulgaris
Mansoura Medical Journal · 01.01.2025 · 55 (1)
DOI: 10.58775/2735-3990.1467 ↗Kurz gefasst
Fachartikel in der Zeitschrift Mansoura Medical Journal, online erschienen am 01.01.2025. Verfasst von Hajar Esamelddin und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Psoriasis is a chronic, immune-mediated dermatosis characterized by dysregulated cutaneous immunity. Platelet-rich fibrin (PRF), an autologous biomaterial concentrated with immunomodulatory cytokines and growth factors, presents a potential novel therapeutic approach by modulating localized inflammatory pathways.
Objective
This study aimed to assess the efficacy and safety of a topical and intralesionally autologous PRF protocol in patients with localized plaque psoriasis.
Methods
In a prospective single-arm trial, sixty adults with mild-to-moderate localized plaque psoriasis (BSA ≤10%, PASI ≤10) were enrolled. PRF was prepared from peripheral blood via low-speed centrifugation without anti-coagulant. Treatment involved bi-weekly intralesionally injections and topical massage of the PRF preparation for 6–8 weeks. Primary outcomes were measured by changes in Psoriasis Area and Severity Index (PASI) and Erythema, Scaling, and Infiltration (ESI) scores. Secondary outcomes included dermatoscopic evaluation and standardized clinical photography.
Results
Treatment with PRF yielded a statistically significant reduction in both PASI and ESI scores (p < 0.001). Complete or near-complete clearance (equivalent to PASI 100) was achieved in 86.7% of patients. Dermatoscopic assessment confirmed a significant resolution of pathological vascular patterns and scaling. No adverse events were reported throughout the study period.
Conclusion
Autologous PRF demonstrates significant efficacy and an excellent safety profile as a novel treatment for localized plaque psoriasis. Its therapeutic effect is likely mediated through local immunomodulation, promoting the resolution of inflammation. These findings position PRF as a promising modality in regenerative dermatology.
Zitieren
APA
Esamelddin, H., Elgyyar, M., & Sultan, M. (2025). Evaluation of Safety and Efficacy of Autologous Platelet-Rich Fibrin in the Treatment of Psoriasis Vulgaris. Mansoura Medical Journal, 55(1). https://doi.org/10.58775/2735-3990.1467
Vancouver
Esamelddin H, Elgyyar M, Sultan M. Evaluation of Safety and Efficacy of Autologous Platelet-Rich Fibrin in the Treatment of Psoriasis Vulgaris. Mansoura Medical Journal. 2025;55(1). doi:10.58775/2735-3990.1467
BibTeX
@article{Esamelddin2025,
author = {Esamelddin, Hajar and Elgyyar, Maha and Sultan, Mohamed},
title = {Evaluation of Safety and Efficacy of Autologous Platelet-Rich Fibrin in the Treatment of Psoriasis Vulgaris},
journal = {Mansoura Medical Journal},
year = {2025},
volume = {55},
number = {1},
doi = {10.58775/2735-3990.1467}
}
EUVIMED